Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like semaglutide (the active ingredient in Ozempic and Wegovy).

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 for obesity.

Participants were instructed to take the semaglutide or placebo tablet in the morning, ... [CI], 0.77 to 0.96; P=0.006), results that showed the superiority of oral semaglutide over placebo ...

In May 2023, when Novo reported that patients on the highest dose (50 mg) of oral semaglutide lost 15% of their weight after 64 weeks, the company said it planned to apply for approval by the end ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, has now completed all dosing. The Study is a three-arm, crossover ...